TrialOrphanet journal of rare diseases2020

Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study).

Amy S Paller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.